ImmunityBio licenses oral vaccine tech from IosBio ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated in trials of ImmunityBio's second-generation human adenovirus 5 (hAd5) COVID-19 vaccine candidate.
Strand Therapuetics, BeiGene to develop mRNA platform tech Strand Therapeutics and BeiGene have entered into an option and license agreement in order to develop and commercialize Strand's messenger RNA (mRNA) treatments for solid tumors.
Codagenix starts phase I trial for COVID-19 vaccine in U.K. The first patient has been dosed in a phase I clinical trial being conducted by Codagenix and the Serum Institute of India of COVI-VAC, a single-dose, intranasal vaccine against the SARS-CoV-2 virus.
Immunocore closes $75M in series C round Immunocore has completed $75 million in series C financing for the development of its novel T-cell receptor bispecific immunotherapies.